Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivaroxaban
Drug ID BADD_D01954
Description Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Indications and Usage Not Available
Marketing Status Prescription
ATC Code B01AF01
DrugBank ID DB06228
KEGG ID D07086
MeSH ID D000069552
PubChem ID 9875401
TTD Drug ID D0KG3R
NDC Product Code 50090-3625; 50458-579; 50458-575; 65015-898; 58032-2029; 55154-1424; 53296-0109; 14799-2023; 55111-966; 76072-1008; 47848-039; 55154-1423; 14501-0079; 65727-050; 52286-0025; 59285-009; 65862-971; 16436-0109; 75945-050; 50090-4468; 53104-7730; 50090-3639; 53747-068; 66022-0203; 50090-4469; 50458-580; 64220-176; 63415-0523; 64552-4049; 50458-578; 46708-899; 82513-0001; 66174-0087; 72969-109; 66039-913; 50458-584; 65372-1193; 50458-577; 55154-1422; 69218-0500
Synonyms Rivaroxaban | 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide | Xarelto | BAY 59-7939 | BAY 59 7939 | BAY 597939
Chemical Information
Molecular Formula C19H18ClN3O5S
CAS Registry Number 366789-02-8
SMILES C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adrenal insufficiency05.01.02.001; 14.11.01.004--
Ageusia07.14.03.003; 17.02.07.001--Not Available
Aggression19.05.01.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.003--Not Available
Alveolitis22.01.01.0010.000535%Not Available
Alveolitis allergic10.01.03.008; 22.01.01.002--Not Available
Amaurosis fugax06.02.02.005; 17.08.04.002; 24.04.06.0060.001071%Not Available
Amnesia17.03.02.001; 19.20.01.001--
Amylase increased13.05.01.009--
Amyotrophic lateral sclerosis17.05.05.0040.000357%Not Available
Anaemia01.03.02.0010.134747%
Anaemia macrocytic01.03.02.002; 14.12.01.0020.000535%Not Available
Anal fistula07.11.05.002--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Aneurysm24.02.01.0010.000745%Not Available
Anger19.04.02.001--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angina unstable02.02.02.004; 24.04.04.004--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Ankle fracture12.04.01.005; 15.08.03.005--
Anosmia17.04.04.001; 22.04.03.006--
Anuria20.01.03.002--Not Available
Anxiety19.06.02.002--
Aortic aneurysm24.02.03.0010.002320%Not Available
Aortic aneurysm rupture24.02.03.0030.000838%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 56 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene